ACR Convergence 2022

November 10-14, 2022. Philadelphia, PA.

View by Number View by Title View Sessions

View by Date

Jump to: View All • a b c d e f g h i j k l m n o p q r s t [u] v w x y z

Abstract Number: 1254

Ultra High‐Frequency Ultrasound of Labial Salivary Glands in Primary Sjögren’s Syndrome: A Promising Tool to Identify Lymphoproliferative Lesions in Unusual Sites
Abstract Number: 2230

Ultra-Rare Genetic Variation in Relapsing Polychondritis: A Whole-Exome Sequencing Study
Abstract Number: 1790

Ultrasound Diagnosis of Calcium Pyrophosphate Crystal Deposition: Which Sites Should Be Scanned?
Abstract Number: 1233

Ultrasound Is Reliable in the Assessment of Muscle Echogenicity in Patients with Rheumatic Diseases: Results of a Multicenter International Web-based Study
Abstract Number: 2229

Ultrasound Localization Microscopy as a New Tool for Takayasu’s Arteritis Activity Assessment, a Deep Insight Within Carotid Wall Inflammation
Abstract Number: 0468

Ultrasound Wall Thickness in the Differential Diagnosis of Atherosclerosis and Large Vessel Giant Cell Arteritis
Abstract Number: 0798

Uncovering the Relationship Between COVID-19 Outcome Severity and Rheumatic Disease
Abstract Number: 1919

Underdiagnosis and Undertreatment of Knee Osteoarthritis in Persons with Type 2 Diabetes: A Cross-sectional Study
Abstract Number: 0669

Understanding How Type I Interferon Modulates Langerhans Cell ADAM17 to Promote Photosensitivity in Lupus
Abstract Number: 2206

Understanding Inter-rater Variability in Scoring of Entheseal Lesions: Results from the Diagnostic Ultrasound Enthesitis Tool (DUET) Study
Abstract Number: 0729

Understanding the Practice and Process of Patient Reported Outcome Measures Collection in North American Pediatric Rheumatology Clinics: A Survey of the Pediatric Rheumatology-Care and Outcomes Improvement Network
Abstract Number: 2076

Unfavorable Outcomes Associated with Current Standard of Care in the Management of Patients with Systemic Lupus Erythematosus
Abstract Number: 0955

Unfavorable Pregnancy Outcome Is Significantly Associated with Corticosteroid Exposure During Pregnancy in Women with RA: Analysis of the Prospective GR2 Cohort
Abstract Number: 1626

Unique Biological Profile of Germinal Centres Within Tertiary Lymphoid Structures in the Salivary Glands of Patients with Sjögren’s Syndrome
Abstract Number: 0744

University of North Carolina and Piedmont Health Collaborative Tele-Rheumatology Project to Optimize Rural Health Specialty Access
Abstract Number: 2197

Unmet Need in Systemic Lupus Erythematosus (SLE) Therapy: High Corticosteroid Use and Poor Adherence and Persistence to SLE Treatments in the US
Abstract Number: 0827

Unpublished Clinical Trials of Major Rheumatic Diseases
Abstract Number: 1823

Unsupervised Cluster Analysis of Clinical and Ultrasound Features Reveals Unique Gout Subtypes: Results from the Egyptian College of Rheumatology (ECR)
Abstract Number: 0909

Unsupervised Clustering Analysis of Circulating Molecular Profiles in Rheumatoid Arthritis Patients Defines Precise CV Risk. Effects of TNFi, IL6Ri, and JAKinibs
Abstract Number: 1127

Unsupervised Clustering Analysis of the Serum Proteome Identifies Systemic Sclerosis Patients with Distinctive Clinical Features
Abstract Number: 1473

Unsupervised Clustering of Lupus Patient-Reported Outcome Data Identifies Patient Groups with Differences in SLEDAI and Physician Global Assessment
Abstract Number: 0425

Upadacitinib Pharmacokinetics and Exposure-Response Relationships for Efficacy and Safety in Axial Spondyloarthritis – Analyses of the Phase 3 Studies (SELECT-AXIS 1 and 2)
Abstract Number: 0192

Upadacitinib versus Adalimumab on Routine Assessment of Patient Index Data 3 (RAPID3) in Patients with Psoriatic Arthritis
Abstract Number: 1388

Updating and Validating the Rheumatic Disease Comorbidity Index to Incorporate ICD-10 Diagnostic Codes
Abstract Number: 1271

Uptake of Rheumatology-Specific Quality Measures Submitted to National Pay-for-Performance Programs: An Analysis of Participants in the RISE Registry
Abstract Number: 1811

Urate Lowering Therapy Initiation in Hospitalized Patients with Acute Gout Flares
Abstract Number: 1828

Urate-lowering Therapy Reduces Non-Episodic Foot Pain in Patients Who Fail to Meet ACR/EULAR 2015 Gout Classification Criteria: An Effect Predicted by Ultrasound
Abstract Number: 1859

Urinary Beta-2 Microglobulin Is a Sensitive Prognostic Marker in Dermatomyositis Patients with Interstitial Lung Disease Positive for Anti-MDA-5 Antibody
Abstract Number: 1478

Urine ALCAM Is a Strong Predictor of Lupus Nephritis
Abstract Number: 1135

Urine Proteomics Implicate Complement C3 and Factor I in Lupus Nephritis Patients with Interstitial Fibrosis and Tubular Atrophy
Abstract Number: 1359

Usability and Acceptability of a Digital Behavioral Therapy for the Management of Fibromyalgia
Abstract Number: 1210

Use of Biologic or Targeted Synthetic Disease Modifying Anti-rheumatic Drugs and the Risk of Lymphoma in Rheumatoid Arthritis
Abstract Number: 1533

Use of Body Mass Index in Prediction of Interstitial Lung Disease Related to Systemic Sclerosis Revealed by Decision Trees
Abstract Number: 0928

Use of Disease Modifying Anti-rheumatic Drugs and Risk of Multiple Myeloma in US Veterans with Rheumatoid Arthritis
Abstract Number: 0969

Use of Gonadotropin-releasing Hormone Agonists for Ovarian Preservation in Patients Receiving Cyclophosphamide for Systemic Lupus Erythematosus: A Meta-analysis
Abstract Number: 1643

Use of Oral Analgesics and Risk of Comorbidities in Osteoarthritis: Findings from Primary Care Settings in the UK
Abstract Number: 0745

Use of Telemedicine in Patients with Systemic Lupus Erythematosus in a Publicly Funded Hospital System
Abstract Number: 0834

Use of the Routine Assessment of Patient Index Data 3 (RAPID3) Questionnaire in the Assessment of Chronic Lower Back Pain
Abstract Number: 1057

Usefulness of REVEAL 2.0 Score as a Prognosis Tool of All-Cause Pulmonary Hypertension in Systemic Sclerosis Patients: A Multicentric Study
Abstract Number: 1978

Using Administrative Health Data to Construct a Frailty Index as a Measure of Susceptibility to Adverse Health Outcomes Among Individuals with Rheumatoid Arthritis
Abstract Number: 1519

Using Galacetin-3 (Gal-3) and Cardiotrophin-1 (CT-1) for Early Detection of Primary Heart Involvement in Systemic Sclerosis as Seen on Cardiac MRI
Abstract Number: 1448

Utility of Digital Signals and Patient Reported Data Gathered in a Decentralized Study to Predict SLE Patient-Reported Flares
Abstract Number: 0474

Utility of Optimization of Tocilizumab Therapy in Giant Cell Arteritis: A Multicenter Study of 471 Patients
Abstract Number: 0725

Utility of Repeat Extractable Nuclear Antigen Antibody Testing- a Retrospective Audit
Abstract Number: 0463

Utilization of a Giant Cell Arteritis Fast-Track Program Independent of Ultrasound at a Single Center
Abstract Number: 0080

Utilization of Biologic and Targeted Disease Modifying Antirheumatic Therapy in Patients with Rheumatoid Arthritis and Breast Cancer
Abstract Number: 1764

Utilization of Electronic Health Record Data to Evaluate the Impact of Urban Environment on Risk of Systemic Lupus Erythematosus Symptoms
Abstract Number: 0064

Utilization of Preventive Services in a Systemic Lupus Erythematosus Population-Based Cohort: A Lupus Midwest Network Study
Abstract Number: 1043

Uveitis in Patients with Axial Spondyloarthritis or Psoriatic Arthritis: Baseline Characteristics and Incidence Rates During Secukinumab and Placebo Comparative Phase: A Post Hoc Analysis
Abstract Number: 1159

Uveitis in Psoriatic Arthritis: Study of 406 Patients in a Single University Center

Jump to: View All • a b c d e f g h i j k l m n o p q r s t [u] v w x y z

All abstracts accepted to ACR Convergence are under embargo once the ACR has notified presenters of their abstract’s acceptance, and cannot be presented at other meetings after this time. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until November 7 at 10:00 AM ET. Journalists with access to embargoed information also cannot release articles before this time.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Permissions and Reprints

For information about abstract permissions and reprints, see ACR Convergence permissions and reprint policies.